SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation

SOCS1 and SOCS3 are key inhibitors of cytokine-induced JAK activity, playing crucial roles in regulating inflammatory and immune responses in skin diseases. These proteins, particularly in epidermal keratinocytes, have been extensively studied for their anti-inflammatory effects. The development of SOCS1 and SOCS3-derived peptides that mimic their kinase inhibitory regions has demonstrated significant anti-inflammatory benefits in experimental models of skin conditions. These findings have been pivotal in the development of JAK inhibitor drugs, some of which are now used clinically to treat atopic dermatitis and psoriasis, with ongoing research into their potential for treating alopecia areata and vitiligo.